세계의 안과용 국소 치료제 시장 전망(-2030년)

Market Overview

The Ophthalmic Topical Therapeutics is estimated to register a significant CAGR of 7.25% during the forecast period (2023 - 2030).

This market is being driven by a few elements, remembering an ascent for geriatric populace and expanding pervasiveness of ophthalmic problems.

There is a rising commonness of ophthalmic problems like refractive blunders, dry eye, glaucoma, eye sensitivities, and age-related macular degeneration internationally which is driving the market development. As per the WHO in October 2021, somewhere around 2.2 billion individuals universally experience the ill effects of vision weakness. The main sources of vision hindrance are refractive blunders and waterfall, the two of which have topical ophthalmic restorative items accessible on the lookout. Essentially, glaucoma is a main source of irreversible visual impairment universally. As indicated by Public Glaucoma Exploration, north of 3 million Americans have glaucoma. As per the WHO in 2021, over 7.7 million individuals experience the ill effects of glaucoma worldwide. The most widely recognized treatment for glaucoma is remedy eye drops like beta-blockers, prostaglandins, Rho-kinase inhibitors, and others that can hold glaucoma back from deteriorating.

Market Segmentation

The Market fragments of Ophthalmic Topical Therapeutics, based on type, incorporates fake tears, against sensitivity, anti-toxin drops, mitigating, antiglaucoma, and others. The Market division, in view of disease type, incorporates dry eye, eye sensitivity, glaucoma, eye disease, retinal issues, uveitis, and others. In view of dose form, the worldwide ophthalmic topical therapeutics industry is divided into eye drops, gels, salves, and others.

The Market division of Ophthalmic Topical Therapeutics, in view of distribution channel, incorporates clinic drug stores, pharmacies, online drug stores, and others.

Regional Insights

The North America ophthalmic topical therapeutics market represented the biggest piece of the pie in 2022. Key variables credited to its rising commonness of eye sickness, rising geriatric populace, and the presence of an enormous number of market players in the district. Moreover, the rising commonness of ophthalmic illnesses is driving the market interest for ophthalmic topical therapeutics in North America. Factors like an expansion in the geriatric populace, progressions in innovative work in optometry, and the expansion in the utilization of ophthalmic medications in emergency clinic drug stores are supposed to expand the interest for ophthalmic topical therapeutics in the US.

Europe ophthalmic topical therapeutics market represented the second-biggest piece of the pie because of expanding geriatric populace in the created nations, globalization of medical services, and rising weight of diabetes and other comorbidities.

The Asia-Pacific ophthalmic topical therapeutics market is supposed to be the quickest developing from 2023 to 2030 because of the rising expanding weight of ophthalmic problems and rising buyer mindfulness, and the developing reception of cutting-edge innovations. Organizations are going into key drives to create and popularize new treatment choices for patients.

Major Players

Key Companies in the market of ophthalmic topical therapeutics includes Santen pharmaceutical co., Ltd. (Japan), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), AbbVie (US), Bausch & Lomb Incorporated (US), Amneal Pharmaceuticals., LLC (US), Teva Pharmaceutical Industries Ltd. (Israel), Alcon (Switzerland), Akorn Operating Company LLC (US), and Viatris Inc. (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 RISE IN GERIATRIC POPULATION
  • 4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
• 4.4 OPPORTUNITIES
  • 4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTTION
  • 5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 ARTIFICIAL TEARS
• 6.3 ANTI-ALLERGY
• 6.4 ANTIBIOTIC DROPS
• 6.5 ANTI-INFLAMMATORY
• 6.6 ANTIGLAUCOMA
• 6.7 OTHERS

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

• 7.1 OVERVIEW
• 7.2 DRY EYE
• 7.3 EYE ALLERGY
• 7.4 GLAUCOMA
• 7.5 EYE INFECTION
• 7.6 RETINAL DISORDERS
• 7.7 UVEITIS
• 7.8 OTHERS

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

• 8.1 OVERVIEW
• 8.2 EYE DROPS
• 8.3 GELS
• 8.4 OINTMENTS
• 8.5 OTHERS

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

• 9.1 OVERVIEW
• 9.2 HOSPITAL PHARMACIES
• 9.3 DRUG STORES
• 9.4 ONLINE PHARMACIES
• 9.5 OTHERS

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 UK
  • 10.3.3 FRANCE
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 JAPAN
  • 10.4.2 CHINA
  • 10.4.3 INDIA
  • 10.4.4 AUSTRALIA
  • 10.4.5 SOUTH KOREA
  • 10.4.6 REST OF ASIA-PACIFIC
• 10.5 REST OF THE WORLD
  • 10.5.1 MIDDLE EAST
  • 10.5.2 AFRICA
  • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 COMPETITIVE BENCHMARKING
• 11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
• 11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
• 11.5 KEY DEVELOPMENT ANALYSIS
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
  • 11.6.2 PARTNERSHIP/COLLABORATION
  • 11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
  • 11.6.4 MERGERS & ACQUISITIONS
• 11.7 MAJOR PLAYERS SALES ANALYSIS
  • 11.7.1 SALES & OPERATING INCOME
• 11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

• 12.1 SANTEN PHARMACEUTICAL CO., LTD.
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 PRODUCTS/SERVICES OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 KEY STRATEGIES
• 12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS/SERVICES OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 KEY STRATEGIES
• 12.3 NOVARTIS AG
  • 12.3.1 COMPANY OVERVIEWS
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS/SERVICES OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 SWOT ANALYSIS
  • 12.3.6 KEY STRATEGIES
• 12.4 ABBVIE INC.
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 SWOT ANALYSIS
  • 12.4.6 KEY STRATEGIES
• 12.5 BAUSCH & LOMB INCORPORATED
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 AMNEAL PHARMACEUTICALS LLC.
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS/SERVICES OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 KEY STRATEGIES
• 12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL ANALYSIS
  • 12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 ALCON
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 AKORN OPERATING COMPANY LLC
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 KEY STRATEGIES
• 12.10 VIATRIS INC.
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS/SERVICES OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 APPENDIX

• 13.1 REFERENCES
• 13.2 RELATED REPORTS